AbbVie has teamed up with Rubin, India, for $1 billion to develop the first MALT-1 inhibitor to treat a series of blood systems:

AbbVie, the US biotech giant, recently teamed up with Lupin, the Indian pharmaceutical giant, to discover and develop a new class of oncology drugs to treat malignant tumors in the blood system.
according to a statement released, Rubin has granted AbbVie exclusive rights to the development and commercialization of Rubin's first-in-class MALT1 (mucosal-related lymphoma congenital protein 1) inhibitor project. MALT-1 is a protein involved in the activity of T-cells and B-cell lymphocytes, and AbbVie plans to develop multiple inhibitors in the MALT1 inhibitor program for a range of hematological cancers, many of which are effective treatment options.
under the terms of the agreement, AbbVie will pay Rubin a $30 million advance to obtain exclusive authorization for the Rubin MALT-1 inhibitor program. After successfully completing the regulatory, development and commercialization milestones, Rubin will be eligible for milestone payments totalling up to $947 million. In addition, Rubin is eligible for a two-figure royalty for future sales of products born out of the partnership, and Rubin retains commercial rights to the project in India.
Rubin's MALT1 program is exploring a new way to treat incurable cancers," said Tom Hudson, vice president of drug discovery at AbbVie, a pharmaceutical company. AbbVie is committed to bringing advanced treatment options to patients. We look forward to working with Rubin's discovery program to bring new hope to patients. Dr
Raj Kamboj, President of Rubin New Drug Discovery and Development (NDDD), said, "We are pleased that our NDDD project has successfully brought India's first pharmaceutical innovation into the field. The MALT1 project is a pioneering drug discovery project, provided exclusively by Rubin at all stages, from discovery to development. We are proud that the Rubin team meets global drug research standards in terms of concept transformation, strategic direction, and unassailable execution.
2010, the Rubin New Drug Discovery and Development (NDDD) team's vision is to use cutting-edge research to develop innovative therapies and bring them globally to address unseeded medical needs in multiple therapeutic areas. At present, NDDD has established highly differentiated and innovative new chemical solid pipelines in the fields of oncology, immunology and metabolic disorder therapy. (Bio Valley)